Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $18.26 in the prior trading day, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $18.07, down -1.04%. In other words, the price has decreased by -$1.04 from its previous closing price. On the day, 6.74 million shares were traded. SRPT stock price reached its highest trading level at $18.44 during the session, while it also had its lowest trading level at $17.86.
Ratios:
Our goal is to gain a better understanding of SRPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 1.00.
Barclays Upgraded its Underweight to Equal Weight on July 29, 2025, while the target price for the stock was maintained at $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Sarepta Therapeutics, Inc. bought 9,265,312 shares for $19.99 per share.
Nicaise Claude sold 2,491 shares of SRPT for $248,203 on Mar 12 ’25. The Director now owns 27,812 shares after completing the transaction at $99.64 per share. On Mar 12 ’25, another insider, Nicaise Claude, who serves as the Director of the company, bought 2,491 shares for $99.65 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 1765681152 and an Enterprise Value of 2329835776. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.71 while its Price-to-Book (P/B) ratio in mrq is 1.30. Its current Enterprise Value per Revenue stands at 0.939 whereas that against EBITDA is 58.033.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.49, which has changed by -0.86834246 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $140.97, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is 1.07%, while the 200-Day Moving Average is calculated to be -74.47%.
Shares Statistics:
The stock has traded on average 12.06M shares per day over the past 3-months and 8924850 shares per day over the last 10 days, according to various share statistics. A total of 97.71M shares are outstanding, with a floating share count of 92.92M. Insiders hold about 4.91% of the company’s shares, while institutions hold 86.74% stake in the company. Shares short for SRPT as of 1755216000 were 18242360 with a Short Ratio of 1.51, compared to 1752537600 on 14856573. Therefore, it implies a Short% of Shares Outstanding of 18242360 and a Short% of Float of 21.9.
Earnings Estimates
The market rating of Sarepta Therapeutics Inc (SRPT) is currently shaped by the ongoing analysis conducted by 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.61, with high estimates of $1.63 and low estimates of -$2.25.
Analysts are recommending an EPS of between $4.26 and -$4.66 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is $3.63, with 16.0 analysts recommending between $6.77 and $1.24.
Revenue Estimates
21 analysts predict $355.08M in revenue for the current quarter. It ranges from a high estimate of $521M to a low estimate of $213.19M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $467.17MFor the next quarter, 21 analysts are estimating revenue of $356.1M. There is a high estimate of $494M for the next quarter, whereas the lowest estimate is $113.19M.
A total of 24 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.37B, while the lowest revenue estimate was $1.68B, resulting in an average revenue estimate of $2.07B. In the same quarter a year ago, actual revenue was $1.9BBased on 23 analysts’ estimates, the company’s revenue will be $1.61B in the next fiscal year. The high estimate is $2.25B and the low estimate is $984.59M.
